Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$119.08 USD

119.08
711,376

+0.58 (0.49%)

Updated Sep 4, 2024 02:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation

by Zacks Equity Research

Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.

Here's Why Investors Should Hold Encompass Health (EHC) Now

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth, attributable to expanding patient admissions, robust expansion endeavors and strong cash-generating abilities.

Shaun Pruitt headshot

Time to Buy Stock in These Pharmaceutical Giants for EPS Growth

by Shaun Pruitt

The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.

Alimera (ALIM) Completes Enrollment in Eye Disease Study

by Zacks Equity Research

Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.

Novo Nordisk (NVO) Collaborates for Gene-Editing Therapies

by Zacks Equity Research

Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.

Zacks.com featured highlights W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis

by Zacks Equity Research

W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis have been highlighted in this Screen of The Week article.

Novo Nordisk (NVO) Announces Positive Obesity Program Data

by Zacks Equity Research

Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.

Sweta Killa headshot

Invest in These Dividend Growth Stocks Amid Default Fears

by Sweta Killa

Dividend stocks W.W. Grainger (GWW), Graphic Packaging (GPK), PulteGroup (PHM), Walmart (WMT) and Novartis (NVS) could be solid choices for your portfolio.

AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab

by Zacks Equity Research

The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.

Novartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress

by Zacks Equity Research

Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.

Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq

by Zacks Equity Research

Alimera's (ALIM) stock jumps 19.4% after the company inks a deal with Eyepoint to acquire additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq

Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now

by Zacks Equity Research

ImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for the company and boost its top-line growth in the next few years.

AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease

by Zacks Equity Research

AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.

Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich

by Zacks Equity Research

Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.

Roche's (RHHBY) MS Drug Meets Goals in the Phase II Study

by Zacks Equity Research

Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.

Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag

by Zacks Equity Research

Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.

Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth

by Zacks Equity Research

Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.

Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline

by Zacks Equity Research

Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.

Neena Mishra headshot

Biotech ETFs Pop on M&A Resurgence

by Neena Mishra

2023 could be a year of heightened biotech dealmaking activity

What Makes Novartis (NVS) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Verizon Communications & United Parcel Service

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).

Here's Why Novartis (NVS) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks.com featured highlights include PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger

by Zacks Equity Research

PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger are part of the Zacks Screen of the Week article.